Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for multiple sclerosis relapses
2018-000620-34Phase 2Terminated
- Sponsor
- Karolinska Institutet
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of imatinib in multiple sclerosis (MS) and clinically isolated syndrome (CIS) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Change in most worsened Functional Systems Score at day 28. Started Mar 2018; status: terminated.
02
Drugs
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on 2018-000620-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000620-34.